JayBWishMD

PubMed

• Hemodialysis Vascular Access: A Historical Perspective on Access Promotion, Barriers, and Lessons for the Future.
  Anatole Besarab, Stanley Frinak, Suresh Margassery, Jay B Wish
  Kidney Medicine. 2024-09-01
• What is the impact of anemia pharmacotherapy on chronic kidney disease progression?
  Hanna T Webb, Jay B Wish
  Expert Opinion on Pharmacotherapy. 2024-07-01
• Care Technician Staffing Ratios in Dialysis Units: In Search of a Balance Between Workforce and Patient Safety.
  Hanna Webb, Jay B Wish
  Kidney Medicine. 2024-03-01

Journal Articles

• Biosimilars—Emerging Role in Nephrology  
  Jay Wish, MD, Journal of the American Society of Nephrology
• Economic issues and future directions in iron management.  
  Wish JB, Semin Dial 12:267-270
• The Controversies in Surveillance: Can It Prolong AV Access Patency? Yes: If Treatment of Stenosis Worked Better.  
  Wish JB, J Vasc Access 12(suppl 4) S22-S23
• ESRD Networks: Past, Present, and Challenges for the Future.  
  Wish JB, Meyer KB, Clin J Am Soc Nephrol
• The economic realities of erythropoiesis-stimulating agent therapy in kidney disease.  
  Wish JB, Kidney Int 70 (Suppl 104):S21-S25
• Application of continuous quality improvement: benefits and barriers.  
  Wish JB, Korean J Nephrol 21(Suppl 2):S194-S196
• Quality oversight of dialysis in the United States.  
  Wish JB, Korean J Nephrol 21 (Suppl 2):S188-S189
• Continuous quality improvement in dialysis units.  
  Pastan S, Wish JB, Adv Renal Replac Ther 8:87-88
• Reports from the ESRD Networks.  
  Wish JB, Adv Renal Replac Ther 7 (4, Suppl.1):S1-S104
• Epidemic end-stage renal disease and nephrology manpower trends: crisis or opportunity?  
  McClellan WM, Cangialose C, Wish JB, Semin Dial 8:275-282
• A consensus on current issues and controversies in iron management in patients with chronic renal failure.  
  Adamson J, Cavill I, Fishbane S, Peterson J, Wish JB, Semin Dial 12:182-194
• Quality control in the ESRD program.  
  Norwalk, CT, Adv Renal Replac Ther 2(2):83-188
• Impotence.  
  Seftel AD, Sweeney P, Wish JB, Semin Dial 7:20-22
• Preventing radiocontrast-induced acute renal failure.  
  Wish JB, Moritz CE, J Crit Illn 5(1):16-31
• Prevalence of arteriovenous fistulas in incident hemodialysis patients: correlation with patient factors that may be associated with maturation failure.  
  Lilly MP, Lynch JR, Wish JB, et al, Am J Kidney Dis 59:541-9
• Hydralazine-induced ANCA-positive pauci-immune glomuerulonephritis: a case report and literature review.  
  Dobre M, Wish J, Negrea L, Ren Fail 31:745-748
• Improving the care of ESRD patients: A success story.  
  McClellan WM, Frankenfield DL, Frederick PR, Helgerson SD, Wish JB, Sugarman JR, Health Care Financ Rev 24:89-100
• Safety of intravenous iron dextran in hemodialysis patients.  
  Fishbane S. Ungureanu V, Maesaka JK, Kaupke CJ, Lim V, Wish J, Am J Kidney Dis 28:529-534
• Join now to see all

Books/Book Chapters

• Dialysis and Transplantation: A Companion to Brenner and Rector’s The Kidney. 
  Chapter: Algorithms and care paths for quality improvement 
  Wish JB, Blondin JEditors: Owen WF, Periera BJG, Sayegh.W.B. Saunders, Orlando
• Principles and Practice of Dialysis. 
  Chapter: Hemodialysis adequacy and the timing of dialysis initiation 
  O’Connor AS, Wish JBEditors: Henrich WL.Lippincott Williams & Wilkins, Philadelphia
• Primer on Kidney Diseases. 
  Chapter: Hematologic manifestations of chronic kidney disease 
  Wish JBEditors: Greenberg A.Saunders, Philadelphia
• Clinical Dialysis. 
  Chapter: Quality, safety and accountability in dialysis 
  Wish JBEditors: Nissenson AR, Fine RN.McGraw Hill, New YorkEdition 4,
• Principles and Practice of Dialysis, third edition. 
  Chapter: Hemodialysis adequacy and the timing of dialysis initiation 
  O’Connor AS, Wish JBEditors: Henrich WL.Lippincott Williams & Wilkins, Philadelphia
• Nephrology Secrets. 
  Chapter: Anemia associated with renal failure, technical aspects of hemodialysis, management of patients with progressive renal failure, hemodialysis: assessing adequacy 
  Wish JBEditors: Hricik DE, Miller RT, Sedor JR.Hanley and Belfus, PhiladelphiaEdition 2,
• Dialysis Therapy. 
  Chapter: Quality improvement 
  Wish JBEditors: Nissenson AR, Fine RN.Hanley & Belfus, Inc, PhiladelphiaEdition 3,
• Dialysis Therapy. 
  Chapter: Quality improvement 
  Wish JBEditors: Nissenson AR, Fine RN.Hanley and Belfus, Philadelphia
• Nephrology Secrets. 
  Chapter: Anemia associated with renal failure, technical aspects of hemodialysis, metabolic acidosis, metabolic alkalosis 
  Wish JBEditors: Hricik DE, Sedor JR, Ganz MB.Hanley and Belfus, Philadelphia
• Management of Medical Problems in Surgical Patients. 
  Chapter: Renal disease and hypertension 
  Wish JB, Cohen JJEditors: Molitch ME.FA Davis Co, Philadelphia
• Principles and Practice of Dialysis. 
  Chapter: Hemodialysis adequacy 
  Lacson E, Wish JBEditors: Henrich WL.Williams and Wilkins, BaltimoreEdition 2,
• Oxford Textbook of Rheumatology. 
  Chapter: Renal involvement in rheumatic disease 
  Cacho CM, Kammer GM, Wish JBEditors: Maddison PJ, et al.Oxford University Press, OxfordEdition 2,
• Clinical Dialysis. 
  Chapter: Assuring quality of care in dialysis patients 
  Wish JBEditors: Nissenson AR, Fine RN, Gentile DE.Andover Publishing, Norwalk, CTEdition 3,
• The High Risk Patient: Management of the Critically Ill. 
  Chapter: Acid-base and electrolyte disorders 
  Wish JB, Cacho CMEditors: Sivak ED, et al.Lea and Fegiber, Philadelphia
• Oxford Textbook of Rheumatology. 
  Chapter: Renal involvement rheumatic disease 
  Wish JB, Kammer GMEditors: Maddison PJ, et al.Oxford University Press, Oxford
• Cecil Essentials of Clinical Medicine. 
  Chapter: Metabolic diseases 
  Hricik DH, Wish JBEditors: Andreoli TE, et al.WB Saunders Co, Philadelphia
• Therapy of Renal Diseases and Related Disorders. 
  Chapter: Disorders of potassium metabolism 
  Kassirer JP, Wish JBEditors: Suki WN, Massry SG.Martinus Nijhoff Publishers, The Hague
• Join now to see all

Abstracts/Posters

• Regional variability in anemia management and hemoglobin in the U.S.
  Reddan D, Frankenfield D, Klassen P, Coladonado J, Szczech L, Johnson C, Besarab A, Rocco M, McClellan W, Wish J, Owen W, J Am Soc Nephrol 12:344A
• Why are catheters still the predominant initial HD access in the US and what effectively reduces their use?
  Wish JB, J Vasc Access 13(suppl 5) S23-S24
• The effects of consistent erythropoiesis-stimulating agent use prior to onset of dialysis on cardiovascular outcomes: a retrospective claims database analysis.
  Wish J, Schulman K, del Aguila M, Nassar G, Provenzano R, Hemodial Int 11:133
• Cost burden of anemia in predialysis cohort of patients with chronic kidney disease.
  Wish J, Schulman K, Law A, J Am Soc Nephrol 17:617A
• Medication burden in patients with chronic kidney disease with and without erythropoiesis-stimulating agents.
  Wish J, Schulman K, Law A, del Aguila M, J Am Soc Nephrol 17:617A
• A retrospective claims analysis of anemia treatment patterns in patients with chronic kidney disease with and without diabetes.
  Wish J, Schulman K, Law A, del Aguila M, J Am Soc Nephrol 17:155A
• Prevalence and treatment of absolute iron deficiency in U.S. hemodialysis patients: findings from the 2005 ESRD Clinical Performance Measures Project.
  Wish JB, Johnson CA, Frankenfield DL, Besarab A, J Am Soc Nephrol 17:320A,
• Extended dosing with darbepoetin alfa in pre-dialysis chronic kidney disease appears to be limited to patients with low dose requirements.
  Wish J, Law AW, Schulman KL, Am J Kidney Dis 47:A61
• Extended intervals using epoetin alfa in pre-dialysis patients with chronic kidney disease appears to be limited to patients with low dose requirements.
  Wish J, Law AW, Schulman KL, Am J Kidney Dis 47:A62
• Correlation between vascular access type hemoglobin level, and Epo dose in prevalent hemodialysis patients: a cohort evaluation of the Renal Network Data System (TRN...
  Teo BW, Kalahasti P, Chand DH, et al, Wish J, J Am Soc Nephrol 16:464A
• Intravenous iron use among adult hemodialysis patients: Results from the 2002 ESRD Clinical Performance Measures Project.
  Johnson CA, Frankenfield DL, Wish JB, J Am Soc Nephrol 11:458A
• The effectiveness of clinical performance measures in hemodialysis patients.
  O’Connor AS, Wish JB, Sehgal AR, J Am Soc Nephrol 14:254-255A
• Correlation between vascular access type, hemoglobin levels, and EPO dose in prevalent hemodialysis patients.
  Wish JB, Brier ME, Kao PF, Aronoff GR, J Am Soc Nephrol 12:419A
• Comparison of platelet activation by polyacrylonitrile and cuprophan dialysis membranes.
  Marchant KK, Anderson JM, Smith MC, Wish JB, ASN Annual Meeting
• Hematocrit and erythropoietin dose are associated with dose of dialysis among adult hemodialysis patients: Results from the 1998 ESRD Core Indicators Project.
  McClellan WM, Frankenfield DL, Johnson CA, Owen WF, Rocco MV, Wish JB, J Am Soc Nephrol 11:287A
• Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 ESRD Core Indicators Project.
  McClellan WM, Frankenfield DL, Johnson CA, Rocco MV, Wish JB, Owen WF, J Am Soc Nephrol 11:287A
• Physician activity reporting: Is it worthwhile?
  Paganini EP, Stark S, Wish J, Aronoff G, Mutterperl R, J Am Soc Nephrol 10:252A
• Continued improvement in anemia management in hemodialysis patients: Report from the 1998 HCFA Core Indicators Project.
  Johnson CA, Frankenfield DL, Rocco MV, Wish JB, J Am Soc Nephrol.10:169A
• management and Hct control in hemodialysis patients. A report from the 1997 HCFA Core Indicators Project.
  Wish JB, Frankenfield DL, Frederick PR, Owen WF, Johnson CA, Rocco MV, J Am Soc Nephrol 9:230A
• Efficacy of ESRD medical evidence screening procedures.
  Segeida GE, Sarsitis I, Wish JB, Coomer R, Eggers P, Stark S, Port FK, Held PJ, J Am Soc Nephrol 8:224A
• Medical appropriateness of initiating chronic dialysis in the U.S.: results of the revised medical evidence report pilot study.
  Wish JB, Webb RL, Levin AS, Port FK, Held PJ, J Am Soc Nephro. 5:345
• Insulin resistance in uremia is due to a post insulin receptor kinase defect(s).
  Caro JF, Sinha MK, McCaleb ML, Wish JB, Lockwood DH, AFCR Annual Meeting
• Characterization of the circulating insulin resistance factor associated with uremia.
  McCaleb ML, Wish JB, Izzo MS, Freeman RB, Lockwood DH, ASCI Annual Meeting
• Nature and severity of vascular access complications in chronic hemodialysis patients.
  Wish JB, Sharp WV, ASN Annual Meeting
• Effect of polyacrylonitrile and cuprophan dialysis membranes on white blood cell and complement component activation.
  Ludgin JR, Naff GB, Spagnuolo P, Wish JB, ASN Annual Meeting
• Join now to see all